Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’

Documenti analoghi

• Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
  di: Mai Katsura, et al.
  Pubblicazione: (2026)
• Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
  di: Andreea Ciudin, et al.
  Pubblicazione: (2026)
• Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
  di: Man Sun, et al.
  Pubblicazione: (2026)
• Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
  di: Lauren Wilson, et al.
  Pubblicazione: (2026)
• Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials
  di: Dirk Müller‐Wieland, et al.
  Pubblicazione: (2026)